Management of Stage IIIA (N2) Non–Small Cell Lung Cancer

Erin A. Gillaspie, Dennis A Wigle

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


There is no consensus as to the optimal management of IIIA (N2) non–small cell lung cancer, nor for the role of surgery in treating this disease stage. Clinical trial evidence struggles to keep up with technology advancement and the evolution of expert opinion. Despite advances in chemotherapeutic regimens, methods of delivery for radiation, and less invasive surgical techniques, survival for patients with stage IIIA-N2 malignancies remains poor. Further developments in both will stimulate and maintain controversy in the field for years to come.

Original languageEnglish (US)
Pages (from-to)271-285
Number of pages15
JournalThoracic Surgery Clinics
Issue number3
StatePublished - Aug 1 2016


  • Adjuvant
  • N2
  • Neoadjuvant
  • Non–small cell lung cancer
  • PORT
  • Stage IIIA
  • Surgery

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Management of Stage IIIA (N2) Non–Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this